Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Autor:
Maria Gomez-Caraballo, Aaron N. Hata, Justin F. Gainor, Eugene J. Mark, Yasushi Goto, Jeffrey A. Engelman, Alona Muzikansky, Michael Lanuti, Emine Bozkurtlar, Tiffany Huynh, Mari Mino-Kenudson, Hironori Uruga
Publikováno v:
Journal of Thoracic Oncology. 12:458-466
Programmed death ligand 1 (PD-L1) expression determined by immunohistochemistry (IHC) may serve as a predictive biomarker for anti-PD-1/PD-L1 therapies; however, little is known about intertumoral heterogeneity of PD-L1 expression determined by IHC i
Publikováno v:
Journal of Thoracic Oncology
The existence of specific cellular subpopulations within primary tumors with increased tumorigenic potential and chemotherapy resistance (tumor-initiating cells, TICs) holds great therapeutic implications. Resistant cells can remain quiescent for lon
Autor:
Takashi Sone, Nagahiro Saijo, Kazuo Kasahara, Asao Sakai, Norihiko Ikeda, Hideharu Kimura, Tokuzo Arao, Kazuko Sakai, Atsushi Horiike, Makoto Nishio, Takeharu Yamanaka, Kazuko Matsumoto, Tatsuo Ohira, Fumiaki Koizumi, Kazuto Nishio
Publikováno v:
Journal of Thoracic Oncology. 6(11):1889-1894
Introduction The epidermal growth factor receptor ( EGFR ) mutation status is a validated biomarker for the stratification of EGFR-tyrosine kinase inhibitor (EGFR-TKIs) treatment in patients with non-small cell lung cancer (NSCLC); however, its use i
Autor:
Filippo de Braud, Gianluca Spitaleri, Massimo Barberis, Lorenzo Spaggiari, Tommaso De Pas, M. Giovannini, Chiara Catania, Caterina Fumagalli, Angelo Delmonte, Francesca Toffalorio, Michela Manzotti
Publikováno v:
Journal of Thoracic Oncology. 6(11):1895-1901
Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib. Although the "common" EGFR mutations, such as the L858R point mutat
Autor:
Paul Germonpré, Robert Gosselin, Lionel Bosquée, Yoshiro Kishi, Jan P. van Meerbeeck, Paul De Vuyst, Kristiaan Nackaerts, Eliane Kellen, Walter De Wever, Joris R. Delanghe, Kevin Hollevoet, Catherine Legrand
Publikováno v:
Journal of thoracic oncology
Introduction: Soluble mesothelin (SM), megakaryocyte potentiating factor (MPF), and osteopontin (OPN) are blood biomarkers of mesothelioma. This study evaluates their use as markers of response to therapy and outcome. Methods: Sixty-two patients with
Autor:
Chen Wu, Sheng Wei, Shaofa Nie, Dongxin Lin, Xiaoping Miao, Dianke Yu, Li Liu, Songyi Lin, Xinyu Zhang, Rong Zhong, Shengyu Duan, Wen Tan, Ying Wang
Publikováno v:
Journal of Thoracic Oncology. 6(11):1793-1800
Introduction Multiple biologically relevant polymorphisms may have more accurate prediction of cancer prognosis compared with single polymorphism because of the modest effect. This study investigated whether the functional polymorphisms in P53 pathwa